FDA Approves First Dual Inhibitor Treatment for IgA Nephropathy

Adults with primary immunoglobulin A (IgA) nephropathy at risk of progressing to kidney failure now have a new weekly injectable option after the FDA granted accelerated approval to atacicept-vymj (Trutakna), according to an FDA news release.¹

Exhibiting a 46% reduction in proteinuria at 9 months, this is the first dual therapy approved for IgA nephropathy, targeting B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) inhibitors.

“IgA remains the most common cause of primary glomerular disease worldwide,” wrote the authors of a study published in the Journal of Clinical Medicine.² “There is significant heterogeneity in clinical presentation, as well as ethnic variability in disease prevalence, clinical course, and response to immunosuppression, but overall, it is often a progressive disease with no established disease-specific treatment.”

This approval represents a major shift in the treatment of an immune-mediated disease that has historically relied on nonspecific management. The pathogenesis of this condition is often described by a 4-hit hypothesis, beginning with increased serum levels of galactose-deficient IgA1 and leading to the eventual deposition of immune complexes that trigger kidney inflammation and damage.^2,3

A New Option in Managing CKD Progression

By targeting BAFF and APRIL, which are essential for B cell survival and maturation, atacicept-vymj effectively decreases the production of these abnormal antibodies. This targeted approach addresses a critical need, as up to 30% of patients traditionally developed kidney failure within 2 decades of diagnosis despite the best available standard of care.^1,2

READ MORE: Finerenone Reduces Cardiovascular, Kidney Events Among Patients with T2D, CKD

For clinical pharmacists, the introduction of this subcutaneous, once weekly injection necessitates careful patient monitoring and counseling regarding its unique safety profile. Because the medication suppresses the immune system, pharmacists must verify that patients are assessed for active infections before beginning therapy. Furthermore, atacicept-vymj can interfere with the efficacy of vaccines.¹

Pharmacists should ensure that live vaccines are not administered within 30 days prior to or during treatment. These precautions are vital as the clinical landscape moves toward a multipronged strategy that combines novel immunomodulators with traditional supportive care.^1,2

Historically, the cornerstone of management has focused on optimal supportive measures, including blood pressure control and the use of renin-angiotensin-aldosterone system (RAAS) blockade with ACE inhibitors or ARBs. Despite these measures remaining essential, many patients continue to face a significant risk of progression.^2,3

The emergence of atacicept-vymj follows other recent advancements, such as approval for the dual endothelin-angiotensin receptor antagonist sparsentan and the targeted-release corticosteroid budesonide.

The Pharmacist’s Key Role in Managing Chronic Kidney Disease

Pharmacists play a pivotal role in navigating this increasingly complex treatment landscape, particularly in managing the high pill burden and nonadherence rates that can reach 74% in this population, according to US Pharmacist.⁴

Beyond clinical management, the economic impact of pharmacist-led interventions in chronic kidney disease (CKD) is substantial. CKD poses a massive financial burden, with Medicare spending for older patients alone surpassing $70 billion.^4,5

A recent cost-benefit analysis in BMJ Open demonstrated that clinical pharmacist-led medication reconciliation and review for patients with kidney disease generated a net benefit of $577 per patient. The study reported a remarkable benefit-to-cost ratio of 115.7:1, highlighting how pharmacist expertise in identifying drug-related problems and optimizing therapy can significantly reduce health care expenditures.⁵

As the FDA continues to monitor atacicept-vymj through confirmatory trials to verify its long-term impact on slowing kidney function decline, pharmacists will be at the forefront of integrating this therapy into practice. Their role in performing comprehensive medication reviews, ensuring proper injection technique, and managing potential complications is more critical than ever as the medical community strives to prevent progression to kidney failure.^1,4,5

This new approval offers a targeted tool to help change the static clinical outcomes observed over the past few decades.²

“Management of CKD focuses on reducing a patient’s cardiovascular risk and decreasing proteinuria through lifestyle modifications and achieving optimal blood pressure and glycemic control,” concluded authors of the US Pharmacist study.⁴ “Through multidisciplinary team management of CKD patients, pharmacists play a pivotal role in identifying such medication-related problems and increasing patient knowledge about the disease state as well as its associated therapies.”

READ MORE: Diabetes Resource Center

REFERENCES

1. FDA approves new treatment to reduce proteinuria in adults with primary immunoglobulin A nephropathy. News Release. FDA. July 7, 2026. Accessed July 7, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-reduce-proteinuria-adults-primary-immunoglobulin-nephropathy

2. Lim RS, Yeo SC, Barratt J, et al. An update on current therapeutic options in IgA nephropathy. J Clin Med. 2024 Feb 7;13(4):947. doi: 10.3390/jcm13040947.

3. Floege J, Rauen T, Tang SCW. Current treatment of IgA nephropathy. Semin Immunopathol. 2021 Oct;43(5):717-728. doi: 10.1007/s00281-021-00888-3.

4. Ambizas EM. Managing chronic kidney disease. US Pharmacist. 2023;48(3):33-39. https://www.uspharmacist.com/article/managing-chronic-kidney-disease

5. Altawalbeh SM, Sallam NM, Al-Khatib M, et al. Clinical pharmacist-led medication reconciliation supplemented with medication review in admitted patients with chronic kidney disease: a cost-benefit analysis. BMJ Open. 2025;15(2):e087232. doi:10.1136/bmjopen-2024-087232